- Home
- BMRC vs IMAB Comparison
BMRC vs IMAB Comparison
Compare BMRC & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- IMAB
- Stock Information
- Founded
- BMRC 1989
- IMAB 2014
- Country
- BMRC United States
- IMAB United States
- Employees
- BMRC N/A
- IMAB N/A
- Industry
- BMRC Major Banks
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BMRC Finance
- IMAB Health Care
- Exchange
- BMRC Nasdaq
- IMAB Nasdaq
- Market Cap
- BMRC 365.9M
- IMAB 384.6M
- IPO Year
- BMRC N/A
- IMAB 2020
- Fundamental
- Price
- BMRC $24.37
- IMAB $3.62
- Analyst Decision
- BMRC Buy
- IMAB Strong Buy
- Analyst Count
- BMRC 4
- IMAB 5
- Target Price
- BMRC $26.25
- IMAB $6.80
- AVG Volume (30 Days)
- BMRC 77.2K
- IMAB 1.8M
- Earning Date
- BMRC 10-27-2025
- IMAB 11-02-2025
- Dividend Yield
- BMRC 4.05%
- IMAB N/A
- EPS Growth
- BMRC N/A
- IMAB N/A
- EPS
- BMRC 0.43
- IMAB N/A
- Revenue
- BMRC $93,409,000.00
- IMAB N/A
- Revenue This Year
- BMRC $59.17
- IMAB N/A
- Revenue Next Year
- BMRC $15.96
- IMAB N/A
- P/E Ratio
- BMRC $57.16
- IMAB N/A
- Revenue Growth
- BMRC 59.35
- IMAB N/A
- 52 Week Low
- BMRC $19.11
- IMAB $0.60
- 52 Week High
- BMRC $27.11
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- BMRC 52.60
- IMAB 44.27
- Support Level
- BMRC $23.86
- IMAB $3.20
- Resistance Level
- BMRC $25.45
- IMAB $4.64
- Average True Range (ATR)
- BMRC 0.50
- IMAB 0.43
- MACD
- BMRC 0.01
- IMAB -0.17
- Stochastic Oscillator
- BMRC 32.08
- IMAB 20.49
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).